Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Context TherapeuticsCNTX -4.05%24 3-Year EBITDA Growth Rate is 23.50% as of Jun. 2026, which is at its 10-year median of 23.50. GuruFocus rates CNTX with a GF Score™ of 24/100. The stock has 1 warning sign investors should review. Among 1,127 Biotechnology companies, Context Therapeutics ranks better than 60.78% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 23.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 7 years, the highest 3-Year average EBITDA Per Share Growth Rate of Context Therapeutics was 48.10% per year. The lowest was -21.60% per year. And the median was 23.50% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Context Therapeutics 3-Year EBITDA Growth Rate Related Terms
CNTX vs QNCX, LITS, KYNB: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Context Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Context Therapeutics 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Context Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Context Therapeutics's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 23.50% mean?
Context Therapeutics (CNTX) has a 3-Year EBITDA Growth Rate of 23.50% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Context Therapeutics and its competitors. This is near median its historical median of 23.50. According to the industry distribution chart, Context Therapeutics ranks #442 out of 1127 companies in the Biotechnology industry, placing it in the top 39.2%.
Is Context Therapeutics' 3-Year EBITDA Growth Rate too high?
Context Therapeutics' current 3-Year EBITDA Growth Rate of 23.50% is near median its 10-year median of 23.50. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.60. Context Therapeutics' value of 23.50% is 61% above this industry median. Based on the distribution chart, Context Therapeutics ranks #442 out of 1127 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Context Therapeutics has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Context Therapeutics' 3-Year EBITDA Growth Rate compare to QNCX and LITS?
According to the Biotechnology industry distribution chart, Context Therapeutics ranks #442 out of 1127 companies for 3-Year EBITDA Growth Rate. This puts Context Therapeutics in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.60. Context Therapeutics' value of 23.50% is 61% above this benchmark. While the company's 10-year median is 23.50 vs. the industry median of 14.60, Context Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.60, based on 1,127 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Context Therapeutics's current 3-Year EBITDA Growth Rate of 23.50% is 61% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Context Therapeutics and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Context Therapeutics's current 3-Year EBITDA Growth Rate is 23.50%, which is near median its own 10-year median of 23.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Context Therapeutics stock overvalued right now?
Context Therapeutics (CNTX) has a current 3-Year EBITDA Growth Rate of 23.50%. The current 3-Year EBITDA Growth Rate is 23.50%, which is near median its 10-year median of 23.50 and 61% above the Biotechnology industry median of 14.60. Context Therapeutics' overall GF Score™ is 24/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Context Therapeutics (CNTX), the current 3-Year EBITDA Growth Rate is 23.50% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
24GF Score
Get the complete analysis for CNTX
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CNTX has been successfully added to your 
